Results 211 to 220 of about 79,311 (270)

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer. [PDF]

ESMO Gastrointest Oncol
Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo Gracian A, Liu Y, van Buuren N, Shao J, Dong M, Chen A, Tejani M, Hecht JR.   +19 more
europepmc   +1 more source

Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study. [PDF]

Ther Adv Med Oncol
Koike T, Kawaguchi Y, Shimokawa M, Otsuka T, Furukawa K, Shinohara Y, Shimokawa H, Yoshihiro T, Shibuki T, Nakazawa J, Arima S, Miwa K, Koga F, Ueda Y, Kubotsu Y, Takeshita S, Nishikawa K, Komori A, Otsu S, Hosokawa A, Sakai T, Oda H, Kawahira M, Arita S, Honda T, Taguchi H, Tsuneyoshi K, Fujita T, Sakae T, Shirakawa T, Mizuta T, Mitsugi K.   +31 more
europepmc   +1 more source

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer. [PDF]

Signal Transduct Target Ther
Chibaudel B, Dourthe LM, André T, Henriques J, Bourgeois V, Etienne PL, Desramé J, Carola E, Dupuis O, Baba-Hamed N, Auby D, Louvet C, Maillard E, Romano O, Tournigand C, Garcia-Larnicol ML, Shacham-Shmueli E, Bird BH, Ghiringhelli F, de Gramont A.   +19 more
europepmc   +1 more source

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer. [PDF]

Oncologist
Wheless MC, Stockton S, Soares HP, Dayyani F, Saeed A, Kim E, Jin N, Yacoub G, Florou V, Ayers GD, Guerrouahen BS, Contreras A, Li L, Ferry-Galow KV, Gore S, Das S, Berlin J.   +16 more
europepmc   +1 more source

Oxaliplatin versus irinotecan as first-line therapy in metastatic colorectal cancer with prior adjuvant treatment: a retrospective study on efficacy, sequential therapy, and the impact of thrombocytopenia. [PDF]

Front Oncol
Shan H, Huang S, Zhou C, Wang M, Du Q.
europepmc   +1 more source

Genetic underpinnings of type-2 diabetes (T2D) with colorectal cancer (CRC): In-silico discovery of common molecular signatures, pathogenetic processes and therapeutic candidates. [PDF]

J Genet Eng Biotechnol
Ahmmed R, Antu US, Noor T, Faysal MF, Sarker A, Mahmud S, Ajadee A, Haque Mollah MN.   +7 more
europepmc   +1 more source

Safety and Efficacy of Concomitant Administration of Nanoliposomal Irinotecan + 5-Fluorouracil/Levo-Leucovorin for Pancreatic Cancer. [PDF]

Cancer Rep (Hoboken)
Wakabayashi A, Tanaka R, Fukumuro Y, Mori K, Sato J, Ishikawa H, Shino M, Kawakami T.   +7 more
europepmc   +1 more source

Systemic Inflammation and Survival in Stage IV Colorectal Cancer: A Retrospective Cohort Study. [PDF]

J Clin Med
Vonica RC, Palade NA, Butuca A, Vornicu VN, Morgovan C, Pumnea M, Cipaian RC, Frum A, Batar F, Solomon A, Vonica-Tincu AL, Dobrea CM, Gligor FG.   +12 more
europepmc   +1 more source

Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer. [PDF]

BMC Cancer
Decraecker M, Le Joncour S, Aurillac V, Sangnier M, Ducerf C, Berroneau A, Rouleau L, Tougeron D, Laplace C, Madau M, Dumon C, Perrier H, Blanc JF.   +12 more
europepmc   +1 more source

Topoisomerase inhibitors in cervical cancer: mechanistic insights and therapeutic strategies. [PDF]

Mol Med
Reddy Y, Pai P, Das I, Nayak S, D'Souza NV, Shetty MG, Sundara BK.   +6 more
europepmc   +1 more source